Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Vascarta Inc
Vascarta Announces NIH Phase I clinical study of VAS-101 in sickle cell disease begins
August 19, 2026
Vascarta Announces Phase I Results of VAS-101 Administered Sublingually in Sickle Cell Disease Patients
June 24, 2026
Vascarta Announces Addition of Richard Serbin to Leadership Team
June 9, 2026
Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis
April 1, 2026